所有图片(1)
选择尺寸
变更视图
15 MG
$225.00
About This Item
经验公式（希尔记法）:
C35H38Cl2N8O4
CAS号:
分子量:
705.63
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
itraconazole
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
CCC(C)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(OCC5COC(Cn6cncn6)(O5)c7ccc(Cl)cc7Cl)cc4
InChI
1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3
InChI 密鑰
VHVPQPYKVGDNFY-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Itraconazole for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
伊曲康唑抑制细胞色素 P-450 依赖性酶，从而抑制麦角固醇的合成。它通过与 14-α 脱甲基酶相互作用来实现该抑制作用，14-α 脱甲基酶是将羊毛甾醇转化为麦角固醇所必需的细胞色素 P-450 酶。麦角固醇是真菌细胞膜的重要组成部分。因此，它的抑制作用导致细胞通透性增加，造成细胞内容物外泄。伊曲康唑还可能抑制内源性呼吸、与膜磷脂相互作用、抑制酵母转化为菌丝体形式、抑制嘌呤摄取，并减少甘油三酸酯和磷脂的生物合成。
合成广谱三唑类抗真菌药。作用方式：抑制细胞色素 P450 依赖性酶，包括 14α-脱甲基酶。抑制作用导致麦角固醇（一种重要的真菌细胞壁成分）的生物合成受到阻止。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險分類
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Gabriele Sass et al.
The American journal of tropical medicine and hygiene, 101(2), 383-391 (2019-06-21)
Trypanosoma cruzi is the etiologic agent of Chagas disease (CD), which can result in severe cardiomyopathy. Trypanosoma cruzi is endemic to the Americas, and of particular importance in Latin America. In the United States and other non-endemic countries, rising case
C H W Koks et al.
Pharmacological research, 46(2), 195-201 (2002-09-11)
The clinical pharmacology of itraconazole is presented in relation to its use in the treatment of fluconazole-resistant oropharyngeal candidosis. The oral solution is a new formulation of itraconazole in which itraconazole is solubilised with the use of cyclodextrin. This formulation
Ritesh Agarwal et al.
Mycoses, 56(5), 559-570 (2013-03-19)
Patients with aspergilloma can be safely managed with supportive therapy in absence of massive haemoptysis. We hypothesised that chronic cavitary pulmonary aspergillosis (CCPA) could also be managed on similar grounds. The aim of this prospective, randomised controlled trial was to
Anil Kumar et al.
The American journal of tropical medicine and hygiene, 90(4), 735-739 (2014-02-05)
Systemic endemic mycoses, such as blastomycosis, are rare in Asia and have been reported as health risks among travelers who visit or reside in an endemic area. Adrenal involvement is rarely seen in blastomycosis and has never been reported from
James D Homans et al.
The Pediatric infectious disease journal, 29(1), 65-67 (2009-11-04)
Coccidioides immitis causes a wide range of disease in humans. Fluconazole and itraconazole are effective treatments. Clinical evidence suggests that itraconazole is equivalent or superior to fluconazole in treating osteoarticular infections in rates of cure and recurrence. We report 2
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
